Caribou Biosciences, Inc. · NASDAQ:CRBU
Caribou Biosciences — Technical Presentation (June 2022)
31 slides from Caribou Biosciences's technical presentation, Jun 10, 2022
Slide 1: ANTLER initial clinical data for CB-010 at EHA 2022
Transformative genome-edited therapies for patients ANTLER initial clinical data for CB-010 at EHA 2022 June 10, 2022 Exhibit 99.2
Slide 2: Forward-looking statements
Forward-looking statements All statements in this presentation, other than statements of historical facts, are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements speak only as of the date of this presentation and a
Slide 3: Introduction
Introduction Rachel Haurwitz, PhD President & CEO Caribou Biosciences, Inc.
Slide 4: Today's guests
Today’s guests Section Chief, New Drug Development Associate Professor, Department of Lymphoma/Myeloma The University of Texas MD Anderson Cancer Center Loretta J. Nastoupil, MD OHC hematologist, medical oncologist, blood and marrow transplant specialist Chair, Cellular Therapy, US Oncology Network
Slide 5: Aiming to set a new therapeutic bar for patients
Aiming to set a new therapeutic bar for patients Our mission is to develop innovative, transformative therapies for patients with devastating diseases through novel genome editing
Slide 6: Persistence is the key to unlocking allogeneic cell therapies
Limited patient access Long vein-to-vein times Not all patients eligible Single dose Broad patient access Immediate availability Suitable for many patients Repeat dosing possible Bridging therapy often required Bridging therapy not required Manufacturing complexity Off-the-shelf availability High pr
Slide 7: CB-010: anti-CD19 allogeneic CAR-T cell therapy
CB-010: anti-CD19 allogeneic CAR-T cell therapy Key attributes CB-010 Conventional allo anti-CD19 CAR-Ts PD-1 KO for enhanced persistence of antitumor activity ✓ X Potentially better initial tumor debulking preclinically ✓ X Potentially better therapeutic index ✓ X Site-specific insertion of CAR int
Slide 8: CB-010 ANTLER results summary
* 40x106 CAR-T cells ; † 80x106 CAR-T cells 1 All data as of May 13, 2022 data cutoff date, data collection ongoing, efficacy measured by Lugano criteria Source: Poster from European Hematology Association (EHA) 2022 Hybrid Congress r/r B-NHL patients in ANTLER had aggressive disease (median 3 prior
Slide 9: With gratitude for patients, caregivers, investigators
With gratitude for patients, caregivers, investigators Clinicaltrials.gov NCT#04637763 MD Anderson Cancer Center, Houston Chao Family Comprehensive Cancer Center / University of California Irvine, Orange Oncology Hematology Care, Cincinnati Baylor Chares A. Sammons Cancer Center, Dallas HonorHealth,
Slide 10: ANTLER Phase 1 trial initial data for CB-010 EHA 2022
ANTLER Phase 1 trial initial data for CB-010 EHA 2022 Loretta J. Nastoupil, MD Section Chief, New Drug Development Associate Professor, Department of Lymphoma/Myeloma The University of Texas MD Anderson Cancer Center
Slide 11: Disclosures
Disclosures LJN has received honorarium for participation in advisory boards from ADC Therapeutics, BMS, Caribou Biosciences, Epizyme, Genentech/Roche, Genmab, Gilead/Kite, Janssen, MorphoSys, Novartis, and Takeda. LJN has received research support from BMS, Caribou Biosciences, Epizyme, Genentech/R
Slide 12: CB-010 ANTLER Phase 1 trial design
CB-010 ANTLER Phase 1 trial design Patients with aggressive disease r/r B-NHL (DLBCL, HGBL, tFL, PMBCL, FL1, MZL, MCL) ≥2 prior lines of chemoimmunotherapy Exclusion: prior CD19-targeted therapy MTD: maximum tolerated dose RP2D: recommended Phase 2 dose 1 Aggressively behaving, with POD24 (high risk
Slide 13: ANTLER patients' baseline and disease characteristics
ANTLER patients’ baseline and disease characteristics 1 Aggressively behaving, with POD24 (high risk) 2 Patients are CD19 CAR-T naïve Characteristics Cohort 1 (N=6) Median age (range), years 65 (62-68) Male, n (%) 5 (83) ECOG performance status, n (%) 0 1 5 (83) 1 (17) Time since first diagnosis, ye
Slide 14: Treatment emergent adverse events (TEAE)
Treatment emergent adverse events (TEAE) Event Cohort 1 (N=6) Any Grade1 N (%) Grade ≥ 3 N (%) Related2 Grade ≥ 3 N (%) Total number of TEAEs 137 39 17 Patients with TEAEs 6 (100) 5 (83) 4 (67) Neutropenia/neutrophil count decreased 5 (83) 5 (83) 1 (17) Thrombocytopenia/platelet count decreased 4 (6
Slide 15: AEs of special interest
AEs of special interest Event Cohort 1 (N=6) Infections3, n (%) Any grade Grade 1 Grade 2 Grade 3 2 (33) 0 (0) 1 (17) 1 (17) Median time to onset, days (range) 8.5 (2-140) Median duration of events, days (range) 5 (1-56) 3 Grade 3, pre-CB-010 infusion. Grade 2, post-CB-010 infusion. None were relate
Slide 16: Kinetics of CB-010
Kinetics of CB-010 Mean PK in first 28 days (N=6)
Slide 17: CB-010: preliminary efficacy
CB-010: preliminary efficacy 6 patients treated with a single infusion at dose level 1 (40x106 CAR-T cells) 6 patients evaluable for efficacy3 100% CR (6/6, best response) 40% CR (2/5) at 6 months 9 months was longest measured CR CRs measured by investigator assessment and central read FL: follicula
Slide 18: Patient case study
Patient case study James H. Essell, MD OHC hematologist, medical oncologist, blood and marrow transplant specialist Chair, Cellular Therapy, US Oncology Network OHC – Specialists in Cancer and Blood Disorders
Slide 19: Original prognosis
Original prognosis Tumor subtype: FL (aggressively behaving, with POD24) Stage: IV Years since diagnosis: 8 Lines of prior therapy: 8 History: multiple relapses and progressive disease, then enrolled on ANTLER trial PET-CT scans2 1 The information presented in this patient case study relates to one
Slide 20: Fireside chat
Fireside chat
Slide 21: Fireside chat with Dr. Nastoupil and Dr. Essell
Fireside chat with Dr. Nastoupil and Dr. Essell Loretta J. Nastoupil, MD Section Chief, New Drug Development Associate Professor, Department of Lymphoma/Myeloma The University of Texas MD Anderson Cancer Center James H. Essell, MD OHC hematologist, medical oncologist, blood and marrow transplant spe
Slide 22: Q&A
Q&A
Slide 23: Open to your questions
Open to your questions Loretta J. Nastoupil, MD Section Chief, New Drug Development Associate Professor, Department of Lymphoma/Myeloma The University of Texas MD Anderson Cancer Center James H. Essell, MD OHC hematologist, medical oncologist, blood and marrow transplant specialist Chair, Cellular T
Slide 24: Closing remarks
Closing remarks Rachel Haurwitz, PhD President & CEO Caribou Biosciences, Inc.
Slide 25: Initial ANTLER data validate Caribou's chRDNA genome-editing platform
Initial ANTLER data are an important step toward validating Caribou’s chRDNA genome-editing platform 100% CR rate1 (6/6, best response), 40% CR rate1 (2/5) at 6 months from a single dose of CB-010 at dose level 1 1st allogeneic CAR-T cell therapy to achieve 100% CR rate, best response Promising init
Slide 26: Caribou pipeline
Program Target Editing Indications Discovery IND enabling Phase 1 Phase 2 Phase 31 Anticipated milestone CAR-T platform with cell therapies for hematologic indications CB-010 CD19 CAR into TRAC; armoring: PD-1 KO r/r B-NHL Additional data expected YE 2022 CB-011 BCMA CAR into TRAC; armoring: B2M KO,
Slide 27: Thank you
cariboubio.com info@cariboubio.com Thank you
Slide 28: Appendix
Appendix
Slide 29: Worldwide NHL incidence and B-NHL survival rates
Worldwide NHL incidence2 B-NHL 5-year post-diagnosis survival rates3 1 National Cancer Institute, Leukemia & Lymphoma Society, Lymphoma Research Foundation 2 Evaluate Pharma, May 2022, www.evaluate.com 3 Cancer Research U.K. Diffuse large B cell lymphoma (DLBCL) Follicular lymphoma (FL) Marginal zon
Slide 30: CB-010: an allogeneic cell therapy that may rival autologous anti-CD19 therapies
CB-010 YESCARTA BREYANZI KYMRIAH none CB-010: an allogeneic cell therapy that may rival autologous anti-CD19 cell therapies EFFICACY SAFETY CB-010: 40x106 CAR-T cells YESCARTA: 2x106 CAR-T cells/kg BREYANZI: 50 to 110x106 CAR-T cells KYMRIAH: 0.6 to 6.0x108 CAR-T cells CB-010 YESCARTA BREYANZI KYMRI
Slide 31: Deeper lymphodepletion protocol does not result in 100% ORR in B-NHL patients
Deeper lymphodepletion protocol does not result in 100% ORR in B-NHL patients B-NHL: B cell non-Hodgkin lymphoma Cy: cyclophosphamide Flu: fludarabine LD: lymphodepletion 1 Turtle CJ et al. Blood. 2015;126(23):184 LD regimen prior to autologous anti-CD19 CAR-T cell therapy infusion N= Objective resp
Caribou Biosciences — Technical Presentation (June 2022) on 6ix